HER-3 status by immunohistochemistry in HER-2- positive metastatic breast cancer patients treated with trastuzumab: Correlation with clinical outcome

Tumori

Volumn 98, Issue 1, 2012, Pages 39-44

  Gori, Stefania ^a   Foglietta, Jennifer ^a   Mameli, Maria Grazia ^b   Stocchi, Lucia ^a   Fenocchio, Daniela ^a   Anastasi, Paola ^a   Iacono, Daniela ^a   Del Sordo, Rachele ^b   Basurto, Carlo ^a   De Angelis, Verena ^a   Sidoni, Angelo ^b  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

HER 2 positive metastatic breast cancer; HER 3 status; Resistance to trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TISSUE LEVEL; BREAST TUMOR; CANCER GRADING; CANCER STAGING; CHEMISTRY; DISEASE COURSE; DRUG RESISTANCE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84863194113     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800105     Document Type: Article

References (14)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Fleming T, Eirmann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastastic breast cancer that overexpresses HER2. N Engl J Med, 344: 783-792, 2001. (Pubitemid 32222155)
2. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antòn A, Lluch A, Kennedy J, O'Byrne K, Conte P, Gren M, Ward C, Mayne K, Extra JM: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 23: 4265-4274, 2005. (Pubitemid 46207001)
3. Vogel CL, Cobleigh M, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 20: 719-726, 2002. (Pubitemid 34111379)
4. Valabrega G, Montemurro F, Aglietta M: Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol, 18: 977-984, 2007. (Pubitemid 47050487)
5. Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, minenza E, De Angelis V, Crinò L: EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol, 20: 648-654, 2009.
6. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ: Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol, 3: 269-280, 2006. (Pubitemid 43731112)
7. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2: 127-137, 2001. (Pubitemid 33674041)
8. Lee-Hoeflich ST, Crocker L, Yao E, Pharm T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM: A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res, 68: 5878-5887, 2008.
9. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baròn AE, Zeng C, Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol, 21: 3798-3807, 2003. (Pubitemid 46606235)
10. Gianni L, Eirmann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 375: 377-384, 2010.
11. Gianni L, Eiermann W, Pusztai L, Semiglazov VF, Hoegel B, Koehler A, Manikhas G, Bates M, Valagussa P, Baselga J: Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol, 26: abstract 504, 2008.
12. Goodman LJ, Weston JK, Mukherjee A, Sperinde J, Paquet A, Williams S, Parry G, Bates M, Koestler W, Lipton A: Quantitative measurement of HER3 total protein (H3T) and association with clinical outcome in HER2-positive metastatic breast cancer patients treated with Trastuzumab. Proc Am Soc Clin Oncol, 27: abstract 1021, 2009.
13. Labuhn M, Vuaroqueax V, Fina F, Schaller A, Nanni-Metellus I, Kung W, Eppenberger-Castori S, Martin PM, Eppenberger U: Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR. Int J Biol Markers, 21: 30-39, 2006.
14. Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, Paton V, Lin CY, Januario T, Ng K, Struss A, Kelsey S, Sliwkowski MX: Clinical activity of gemcitabine plus pertuzumab in platinum-resistent ovarian, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol, 28: 1215-1223, 2010.